Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rodatristat ethyl - Sumitomo Pharma America

Next Previous
Drug Profile

Rodatristat ethyl - Sumitomo Pharma America

Alternative Names: KAR-5585; RVT-014; RVT-1201

Latest Information Update: 28 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Karos Pharmaceuticals
  • Developer Altavant Sciences; Sumitomo Pharma America
  • Class Antifibrotics; Antihypertensives; Aza compounds; Chlorobenzenes; Fluorinated hydrocarbons; Hepatoprotectants; Pyrimidines; Small molecules; Spiro compounds
  • Mechanism of Action Tryptophan hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pulmonary arterial hypertension
  • No development reported Idiopathic pulmonary fibrosis; Non-alcoholic fatty liver disease; Sarcoidosis

Most Recent Events

  • 28 Jan 2025 No recent reports of development identified for phase-I development in Idiopathic-pulmonary-fibrosis in USA (PO)
  • 28 Jan 2025 No recent reports of development identified for research development in Non-alcoholic-fatty-liver-disease in USA
  • 09 Sep 2023 Pharmacokinetics and adverse events data from a phase IIb ELEVATE 2 trial in Pulmonary arterial hypertension presented at 33rd Annual Congress of the European Respiratory Society (ERS-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top